An observational study in Leukemia, sponsored by Children's Oncology Group. Completed. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2016-05-18.
Sponsored by Children's Oncology Group · Observational
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying blood and tumor tissue samples from young patients with acute myeloid leukemia.
OBJECTIVES:
OUTLINE: This is a multicenter study.
Archived samples from pediatric patients with acute myeloid leukemia are analyzed for Mer and Axl expression by flow cytometry and western blot assays.
5,475 studies on the registry are indexed under Leukemia; 629 are open to participants now.
This study's planned enrollment of 52 is below the median of 120 across 747 observational studies indexed under Leukemia.
Browse Leukemia studies →Children's Oncology Group is the lead sponsor of 447 studies on the registry; 35 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 11 (92%) have results posted.
Counted across the registry records on this site, refreshed daily.
Diagnosis of acute myeloid leukemia
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Expression of Mer and Axl
Association of abnormal expression of Mer and Axl with induction failure or relapse
No study locations are listed for this record.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.